ReviewBest practice & research. Clinical gastroenterology2011
DFMO: targeted risk reduction therapy for colorectal neoplasia.
Review in Best practice & research. Clinical gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.Frontiers in oncology · 2023Pooled it
- Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.Cell reports. Medicine · 2023Trial
- A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.International journal of cancer · 2020Trial
- Eflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms: A Systematic Review.Gastroenterology research · 2025Review
- MicroRNA-378a-3p prevents initiation and growth of colorectal cancer by fine tuning polyamine synthesis.Cell & bioscience · 2022Article
- Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study.Metabolites · 2022Article
- S-adenosylmethionine: A metabolite critical to the regulation of autophagy.Cell proliferation · 2020Review
- A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors.Cancer chemotherapy and pharmacology · 2020Article
- Calcium Permeable Channels in Cancer Hallmarks.Frontiers in pharmacology · 2020Review
- DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.Cancer research · 2019Article
- Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.Cancer reports (Hoboken, N.J.) · 2019Review
- Bioactive polyamine production by a novel hybrid system comprising multiple indigenous gut bacterial strategies.Science advances · 2018Article
- In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer.Scientific reports · 2017Article
- Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms.Frontiers in pharmacology · 2017Review
- Prevention of Colorectal Neoplasia.Clinics in colon and rectal surgery · 2016Review
- ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.American journal of cancer research · 2016Article
- NSAIDs and Colorectal Cancer Control: Promise and Challenges.Current pharmacology reports · 2015Article
- Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells.Journal of neuro-oncology · 2015Article
- The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.The Journal of pharmacology and experimental therapeutics · 2015Review
- Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.Cancer prevention research (Philadelphia, Pa.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.